Immune control by amino acid catabolism during tumorigenesis and therapy

[1]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[2]  E. McNeill,et al.  The metabolite BH4 controls T cell proliferation in autoimmunity and cancer , 2018, Nature.

[3]  David C. Smith,et al.  Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Prendergast,et al.  Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond , 2018, Seminars in Immunopathology.

[5]  A. Pegg,et al.  Polyamine metabolism and cancer: treatments, challenges and opportunities , 2018, Nature Reviews Cancer.

[6]  X. Tian,et al.  Abstract 192: Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1 , 2018, Tumor Biology.

[7]  P. Singh,et al.  Abstract 1701: EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic , 2018, Immunology.

[8]  Shi Zhe,et al.  Abstract 2736: Preclinical pharmacologic and pharmacodynamic studies of a novel and potent IDO1 inhibitor D-0751 , 2018 .

[9]  K. Morrissey,et al.  Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors , 2018, Journal of Immunotherapy for Cancer.

[10]  G. Georgiou,et al.  Reversal of IDO-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme , 2018, Nature Biotechnology.

[11]  James R. Anderson,et al.  Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. , 2018 .

[12]  D. Samuel,et al.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.

[13]  G. Barber,et al.  Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. , 2018, Cancer cell.

[14]  Ken Garber,et al.  A new cancer immunotherapy suffers a setback. , 2018, Science.

[15]  Shanshan Zhu,et al.  High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer , 2018, Front. Immunol..

[16]  D. Munn,et al.  Apoptotic cell–induced, TLR9-dependent AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans , 2018, Nature Immunology.

[17]  C. James,et al.  IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma , 2018, Clinical Cancer Research.

[18]  J. Cleveland,et al.  Role of Polyamines in Immune Cell Functions , 2018, Medical sciences.

[19]  Lijun Sun,et al.  A patent review of IDO1 inhibitors for cancer , 2018, Expert opinion on therapeutic patents.

[20]  S. Jolly,et al.  IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. , 2018, Cancer research.

[21]  Masahide Takahashi,et al.  ASC amino acid transporter 2, defined by enzyme‐mediated activation of radical sources, enhances malignancy of GD2‐positive small‐cell lung cancer , 2018, Cancer science.

[22]  A. Bass,et al.  Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity. , 2018, Gastroenterology.

[23]  K. Takeda,et al.  The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion , 2017, International journal of molecular sciences.

[24]  G. Prendergast,et al.  Discovery of IDO1 Inhibitors: From Bench to Bedside. , 2017, Cancer research.

[25]  T. MacDonald,et al.  PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708) , 2017 .

[26]  T. Cloughesy,et al.  ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS , 2017 .

[27]  Gregory A. Wyant,et al.  mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient , 2017, Cell.

[28]  J. Galipeau,et al.  The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells , 2017, Oncotarget.

[29]  C. Link,et al.  Abstract 4076: A novel prodrug of indoximod with enhanced pharmacokinetic properties , 2017 .

[30]  J. Desai,et al.  Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial , 2017 .

[31]  D. Munn,et al.  Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma , 2017 .

[32]  E. Schmidt,et al.  Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037. , 2017 .

[33]  David C. Smith,et al.  Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037. , 2017 .

[34]  David C. Smith,et al.  Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. , 2017 .

[35]  E. D. Bal de Kier Joffé,et al.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer , 2017, Journal of Cancer Research and Clinical Oncology.

[36]  J. Hassell,et al.  Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts , 2017, Oncotarget.

[37]  L. Capelle,et al.  Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. , 2017, European journal of cancer.

[38]  N. Kerkvliet,et al.  Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases? , 2017, Current opinion in toxicology.

[39]  A. Badawy.  Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements , 2017, Neuropharmacology.

[40]  P. O'dwyer,et al.  First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies , 2017, Clinical Cancer Research.

[41]  R. Sullivan,et al.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  D. Munn,et al.  ACTR-53. INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS , 2016 .

[43]  S. Ariyan,et al.  Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Wesseling,et al.  Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. , 2016, Neuro-oncology.

[45]  J. Pouysségur,et al.  Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. , 2016, Cancer research.

[46]  W. Muster,et al.  Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment , 2016 .

[47]  B. Somer,et al.  Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis. , 2016 .

[48]  D. Munn,et al.  Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. , 2016 .

[49]  D. Munn,et al.  Virus Infections Incite Pain Hypersensitivity by Inducing Indoleamine 2,3 Dioxygenase , 2016, PLoS pathogens.

[50]  D. Munn,et al.  STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. , 2016, Cancer research.

[51]  D. Munn,et al.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.

[52]  M. Maes,et al.  The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders. , 2016, Current pharmaceutical design.

[53]  C. Link,et al.  Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. , 2016 .

[54]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[55]  J. Malvehy,et al.  Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis , 2016, ESMO Open.

[56]  G. Barber,et al.  Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. , 2016, Cell reports.

[57]  Xiangshi Tan,et al.  Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.

[58]  R. Dantzer,et al.  Exercise, inflammation, and fatigue in cancer survivors. , 2016, Exercise immunology review.

[59]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[60]  A. D’Alessandro,et al.  A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. , 2015, Cancer research.

[61]  Loise M. Francisco,et al.  The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment , 2015, Science Advances.

[62]  J. Wolchok,et al.  Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. , 2015, Cell reports.

[63]  T. McGaha,et al.  The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity , 2015, Proceedings of the National Academy of Sciences.

[64]  Zhe-Sheng Chen,et al.  5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway , 2015, Oncotarget.

[65]  C. Koumenis,et al.  Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma , 2015, Scientific Reports.

[66]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[67]  T. Berghmans,et al.  Medical anticancer treatment of lung cancer associated with comorbidities: a review. , 2015, Lung cancer.

[68]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[69]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[70]  B. Brew,et al.  Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology , 2014, PloS one.

[71]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[72]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[73]  G. Prendergast,et al.  IDO2 in Immunomodulation and Autoimmune Disease , 2014, Front. Immunol..

[74]  J. Renauld,et al.  Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues , 2014, Cancer Immunology Research.

[75]  E. Dees,et al.  A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors , 2014, Oncotarget.

[76]  T. MacDonald,et al.  The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma , 2014, Journal of Immunotherapy for Cancer.

[77]  D. Munn,et al.  Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis , 2014, The Journal of Immunology.

[78]  Y. Cheng,et al.  Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.

[79]  D. Munn,et al.  Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance , 2014, Proceedings of the National Academy of Sciences.

[80]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[81]  A. von Deimling,et al.  Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR , 2014, Oncotarget.

[82]  Xinming Wang,et al.  Role of aryl hydrocarbon receptor in cancer. , 2013, Biochimica et biophysica acta.

[83]  B. Stockinger,et al.  Differential Influences of the Aryl Hydrocarbon Receptor on Th17 Mediated Responses in vitro and in vivo , 2013, PloS one.

[84]  Leonie Unterholzner.  The interferon response to intracellular DNA: why so many receptors? , 2013, Immunobiology.

[85]  B. Baban,et al.  Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses , 2013, The Journal of Immunology.

[86]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[87]  J. Khan,et al.  Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. , 2013, Blood.

[88]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[89]  A. von Deimling,et al.  The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. , 2013, Cancer research.

[90]  Huidong Shi,et al.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. , 2013, Immunity.

[91]  R. Schreiber,et al.  Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy , 2013, Annals of the New York Academy of Sciences.

[92]  Linda V. Sinclair,et al.  Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation , 2013, Nature Immunology.

[93]  Charles J. Link,et al.  Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .

[94]  The American Association for Cancer Research Annual Meeting. , 2013, Oncology.

[95]  G. Prendergast,et al.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR , 2012, Oncoimmunology.

[96]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[97]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[98]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[99]  D. Munn,et al.  Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance , 2012, Immunological investigations.

[100]  Shuxing Wang,et al.  Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. , 2012, The Journal of clinical investigation.

[101]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[102]  S. Knox,et al.  Abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[103]  B. Baban,et al.  Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells , 2012, The Journal of Immunology.

[104]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[105]  Rahul Shinde,et al.  Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.

[106]  C. Kyriakopoulos,et al.  Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective , 2012, Journal of immunotherapy.

[107]  A. Tefferi,et al.  Abscopal effect in a patient with melanoma. , 2012, New England Journal of Medicine.

[108]  S. Wang,et al.  Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T Cells In Situ and Lymph Node Metastasis , 2011, Clinical & developmental immunology.

[109]  M. Weller,et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.

[110]  C. Sousa.  Faculty Opinions recommendation of Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. , 2011 .

[111]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[112]  S. Bicciato,et al.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells , 2011, Nature Immunology.

[113]  Loise M. Francisco,et al.  Physiologic Control of IDO Competence in Splenic Dendritic Cells , 2011, The Journal of Immunology.

[114]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[115]  P. Couppié,et al.  T Cell Reactivity against Mycolyl Transferase Antigen 85 of M. tuberculosis in HIV-TB Coinfected Subjects and in AIDS Patients Suffering from Tuberculosis and Nontuberculous Mycobacterial Infections , 2010, Clinical & developmental immunology.

[116]  B. Baban,et al.  Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. , 2010, Immunity.

[117]  F. Fallarino,et al.  IDO Upregulates Regulatory T Cells via Tryptophan Catabolite and Suppresses Encephalitogenic T Cell Responses in Experimental Autoimmune Encephalomyelitis , 2010, The Journal of Immunology.

[118]  Kazuya Masuda,et al.  Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism , 2010, Proceedings of the National Academy of Sciences.

[119]  J. Fechner,et al.  An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.

[120]  C. J. Omiecinski,et al.  Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[121]  P. Wallace,et al.  Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. , 2009, Cancer research.

[122]  C. L. Costantino,et al.  Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival , 2009, Cell cycle.

[123]  C. L. Costantino,et al.  Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.

[124]  G. Weiner.  CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. , 2009, Advanced drug delivery reviews.

[125]  B. Quesnel,et al.  Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. , 2009, Leukemia research.

[126]  G. Prendergast,et al.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.

[127]  F. Matsumura,et al.  Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. , 2008, Biochemical and biophysical research communications.

[128]  D. Munn,et al.  The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation1 , 2008, The Journal of Immunology.

[129]  L. Bubendorf,et al.  High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. , 2008, European journal of cancer.

[130]  G. Prendergast,et al.  A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase , 2008, Oncogene.

[131]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[132]  Gregory I. Elliott,et al.  3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis , 2007, Proceedings of the National Academy of Sciences.

[133]  D. Munn,et al.  The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. , 2007 .

[134]  B. Baban,et al.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.

[135]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[136]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[137]  D. Munn,et al.  A high‐affinity, tryptophan‐selective amino acid transport system in human macrophages , 2006, Journal of leukocyte biology.

[138]  P. Puccetti,et al.  Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. , 2006, Trends in microbiology.

[139]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[140]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[141]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[142]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[143]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[144]  Y. Nishimura,et al.  AN INTERIM ANALYSIS , 2005 .

[145]  R. Germain,et al.  A New Year for Immunity , 2005 .

[146]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[147]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[148]  D. Munn,et al.  Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1 , 2004, The Journal of Immunology.

[149]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[150]  D. Munn,et al.  Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma , 2003, Laboratory Investigation.

[151]  R. Dantzer,et al.  Cytokines and depression: The need for a new paradigm , 2003, Brain, Behavior, and Immunity.

[152]  D. Munn,et al.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division , 2002, Immunology.

[153]  D. Ron,et al.  Translational control in the endoplasmic reticulum stress response. , 2002, The Journal of clinical investigation.

[154]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[155]  D. Munn,et al.  Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection , 2002, International journal of cancer.

[156]  S. Todryk.  A sense of tumour for the immune system , 2002, Immunology.

[157]  J. Moulinoux,et al.  Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. , 1995, Journal of immunology.

[158]  R. Stocker,et al.  Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. , 1994, The Journal of biological chemistry.

[159]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[160]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[161]  C C Edwards,et al.  The need for a new paradigm. , 1970, Journal of the American Pharmaceutical Association.

[162]  R. C. Macridis.  A review , 1963 .